Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Our years of manufacturing experience and refined products provide you with better protection
Through tailored products, adaptable service and packaging choices, and unwavering support, Alpha Lifetech Inc. guarantees that researchers have access to the most fitting and efficient tools tailored to their research endeavors.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring the generation of high-quality leads that align with CAR-T project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian — critical for reducing immunogenicity in CAR-T constructs.
Our Membrane Proteomics platform offers comprehensive identification, quantification, and characterization of CAR-T target membrane proteins, providing valuable insights into their functions and interactions.
Alpha Lifetech offers native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Goat, Camel and Llama — ideal for CAR-T nanobody screening.
Understanding the transformative role of single-domain antibodies in next-generation cancer immunotherapy
Nanobodies — the variable domains of camelid heavy-chain antibodies (VHH) — offer unique structural advantages for CAR-T cell design. Their small size (~15 kDa), high thermal stability, superior tissue penetration, and ease of genetic engineering make them ideal building blocks for next-generation CAR constructs targeting solid tumors, hematologic malignancies, and beyond.
Traditional CAR-T constructs rely on scFv antibody fragments that can suffer from aggregation, mispairing, and poor expression on T-cell surfaces. Nanobodies, with their single-domain architecture, eliminate these issues entirely. Their compact structure allows them to access epitopes on tumor antigens that are cryptic or sterically hindered for conventional antibodies — such as enzyme active sites and receptor clefts — enabling CAR-T cells to recognize a broader repertoire of cancer-associated targets including HER2, EGFR, CD19, BCMA, and mesothelin with unprecedented specificity.
The modular nature of nanobodies enables flexible CAR architecture engineering. Multi-specific CARs incorporating tandem nanobody domains can simultaneously target two or more tumor antigens, dramatically reducing the risk of antigen escape — a leading cause of CAR-T therapy relapse. Bispecific nanobody-CARs targeting CD19/CD22 or BCMA/CD38 dual epitopes are already demonstrating superior preclinical outcomes. Furthermore, the short CDR3 loop of VHH domains provides remarkable stability under the reductive intracellular environment of T cells, ensuring consistent CAR surface expression throughout the therapeutic window.
The global nanobody therapeutics market was valued at over USD 1.2 billion in 2023 and is projected to exceed USD 6 billion by 2032, growing at a CAGR of over 19%. Major pharmaceutical players including Sanofi (Ablynx acquisition), Merck, and Novartis are actively investing in nanobody-based CAR-T pipeline assets. Biotech startups such as Precirix, Cartesian Therapeutics, and Imvax are pioneering clinical-stage nanobody-CAR programs. The cost-effectiveness of nanobody production in microbial systems (E. coli, yeast) compared to mammalian cell-derived scFv also provides significant manufacturing scalability advantages for commercial CAR-T production.
One of the most formidable challenges for CAR-T therapy has been the immunosuppressive tumor microenvironment (TME) of solid tumors. Nanobody-CARs offer a compelling solution: their ultra-small size (roughly one-tenth of a conventional antibody) enables superior diffusion through the dense extracellular matrix of solid tumors. Preclinical studies have demonstrated that VHH-based CARs targeting GD2, EGFRvIII, and CEA achieve 3–5x greater tumor infiltration compared to conventional scFv-CARs, translating into significantly improved anti-tumor efficacy in xenograft models of lung, breast, and glioblastoma cancers.
Key technological and commercial trends shaping the nanobody-CAR-T ecosystem
Machine learning platforms are accelerating VHH lead identification by predicting binding affinity, developability, and immunogenicity in silico — reducing discovery timelines from months to weeks.
Nanobody-CARs are ideal for allogeneic CAR-T manufacturing due to their genetic compactness, enabling efficient integration into CRISPR-edited donor T cells for scalable off-the-shelf therapies.
Tandem and loop VHH architectures enable simultaneous multi-antigen targeting within a single CAR construct, addressing tumor heterogeneity and antigen escape mechanisms.
Beyond oncology, nanobody-CARs targeting autoreactive B cells and plasma cells are entering clinical trials for lupus, myasthenia gravis, and systemic sclerosis — a rapidly expanding market.
Lipid nanoparticle (LNP) and viral vector systems encoding nanobody-CAR constructs are enabling in vivo T-cell reprogramming, eliminating the need for ex vivo cell manufacturing entirely.
Asia-Pacific, particularly China and South Korea, is emerging as a major hub for nanobody-CAR-T development, with regulatory frameworks increasingly accommodating accelerated approval pathways for cell therapies.
Alpha Lifetech provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, and hybridoma technology.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies ideally suited for CAR-T construct development. Our end-to-end workflow covers immunization, library construction, panning, screening, and hit characterization.
Read More
The aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services — enabling novel targeting strategies complementary to nanobody-CAR approaches.
Read More
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species. These services provide critical reagents and leads for CAR-T target validation, epitope mapping, and companion diagnostic development.
Read More
We also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for nanobody-based CAR-T antibody development. These enabling technologies accelerate the transition from nanobody lead identification to CAR construct validation and preclinical development.
Read More
What our global partners say about Alpha Lifetech's nanobody and CAR-T discovery services
Exceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
Quality products! Our experience with Alpha Lifetech has been nothing short of outstanding. Their VHH nanobody libraries delivered exceptional hit rates for our CAR-T antigen binding domain program.
Reliable, responsive, and results-driven — Alpha Lifetech. Their nanobody affinity maturation service significantly improved our CAR-T construct's tumor cell killing potency.
Simply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner in our CAR-T therapy development pipeline.
Alpha Lifetech's membrane protein expression platform was instrumental in generating the high-quality antigens we needed for nanobody immunization and CAR-T target validation. Highly recommended.
The turnaround time and scientific rigor of Alpha Lifetech's single B cell sorting service exceeded our expectations. A truly world-class partner for antibody and nanobody discovery.
Explore our full range of nanobody and antibody discovery services supporting every stage of CAR-T therapy development
Partner with Alpha Lifetech Inc. — your trusted expert in nanobody discovery, antibody engineering, and CAR-T therapy development. Contact our scientific team today to design a customized discovery strategy for your project.
Get Started Today